Douglas J. Swirsky has been an independent member of our Board and also served as Chairman of the Audit Committee since November 2017. He also serves on our Compensation Committee. Since January 2018, Mr. Swirsky is the President and Chief Financial Officer of Rexahn Pharmaceuticals, Inc., or Rexahn, a publicly-traded clinical-stage oncology company. Prior to joining Rexahn, Mr. Swirsky was President, CEO, and a director of GenVec, Inc., or GenVec, a publicly traded biotechnology company; a position he held from 2013 through the sale of the company in 2017. He joined GenVec in 2006 as chief financial officer, treasurer, and corporate secretary. Prior to joining GenVec, Mr. Swirsky was a managing director and the head of life sciences investment banking at Stifel Nicolaus from 2005 to 2006 and held investment banking positions at Legg Mason from 2002 until Stifel Financial’s acquisition of the Legg Mason Capital Markets business in 2005. Mr. Swirsky has also previously held investment banking positions at UBS, PaineWebber, and Morgan Stanley. His experience also includes positions in public accounting and consulting. Mr. Swirsky is presently chairman of the board of directors of Fibrocell Science, Inc. and the chairman of the board of directors of Cellectar Biosciences, Inc. Mr. Swirsky received his B.S. in Business Administration from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University. Mr. Swirsky is a certified public accountant and a CFA® charter holder.